JP2013515739A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515739A5
JP2013515739A5 JP2012546185A JP2012546185A JP2013515739A5 JP 2013515739 A5 JP2013515739 A5 JP 2013515739A5 JP 2012546185 A JP2012546185 A JP 2012546185A JP 2012546185 A JP2012546185 A JP 2012546185A JP 2013515739 A5 JP2013515739 A5 JP 2013515739A5
Authority
JP
Japan
Prior art keywords
composition
rhodostomin variant
subject
seq
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012546185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515739A (ja
JP5739908B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/061738 external-priority patent/WO2011079175A1/en
Publication of JP2013515739A publication Critical patent/JP2013515739A/ja
Publication of JP2013515739A5 publication Critical patent/JP2013515739A5/ja
Application granted granted Critical
Publication of JP5739908B2 publication Critical patent/JP5739908B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012546185A 2009-12-23 2010-12-22 血管形成関連の眼疾患の処置のための組成物および方法 Expired - Fee Related JP5739908B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28962409P 2009-12-23 2009-12-23
US61/289,624 2009-12-23
PCT/US2010/061738 WO2011079175A1 (en) 2009-12-23 2010-12-22 Compositions and methods for the treatment of angiogenesis-related eye diseases

Publications (3)

Publication Number Publication Date
JP2013515739A JP2013515739A (ja) 2013-05-09
JP2013515739A5 true JP2013515739A5 (enExample) 2014-02-06
JP5739908B2 JP5739908B2 (ja) 2015-06-24

Family

ID=44151942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012546185A Expired - Fee Related JP5739908B2 (ja) 2009-12-23 2010-12-22 血管形成関連の眼疾患の処置のための組成物および方法

Country Status (14)

Country Link
US (1) US9044436B2 (enExample)
EP (1) EP2515926A4 (enExample)
JP (1) JP5739908B2 (enExample)
KR (1) KR20120130752A (enExample)
CN (1) CN102883738A (enExample)
AR (1) AR079706A1 (enExample)
AU (1) AU2010336475A1 (enExample)
BR (1) BR112012015188A8 (enExample)
CA (1) CA2782796A1 (enExample)
MX (1) MX2012007416A (enExample)
NZ (1) NZ600544A (enExample)
RU (1) RU2012131251A (enExample)
TW (1) TWI581801B (enExample)
WO (1) WO2011079175A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
EP2456454A4 (en) * 2009-07-20 2013-03-20 Univ Nat Cheng Kung FOR AV-3-INTEGRIN SELECTIVE POLYPEPTIDE AND PHARMACEUTICAL USES THEREOF ASSOCIATED WITH A HUMAN SERUM ALUMINUM (HSA) VARIATION
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
WO2015147616A1 (ko) * 2014-03-28 2015-10-01 연세대학교 산학협력단 Rgd 모티프를 포함하는 펩타이드 또는 단백질을 포함하는 신경염증 예방, 억제 또는 치료용 조성물
CA2958906C (en) * 2014-08-22 2021-05-04 National Cheng Kung University Disintegrin variants and pharmaceutical uses thereof
WO2016108669A1 (ko) 2014-12-31 2016-07-07 주식회사 휴온스 Rgd 모티프 함유 펩티드 또는 이의 단편을 포함하는 화상 및 녹내장 치료, 피부 주름 개선 및 발모 촉진용 조성물
MX382540B (es) * 2015-06-28 2025-03-13 Allgenesis Biotherapeutics Inc Proteinas de fusion para inhibir la angiogenesis
BR112018003179A2 (pt) 2015-08-20 2018-09-25 Albumedix As conjugados e variantes de albumina
US12304037B2 (en) 2021-11-03 2025-05-20 Aob Products Company Torque driver
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
KR20250021281A (ko) 2023-08-04 2025-02-12 주식회사 넥스세라 콜라겐 타입 i 및 색소 상피성 인자 펩타이드를 유효성분으로 포함하는 안구 혈관신생 질환의 예방 또는 치료용 점안제 조성물
WO2025033777A1 (ko) 2023-08-04 2025-02-13 주식회사 넥스세라 콜라겐 타입 i 및 색소 상피성 인자 펩타이드를 유효성분으로 포함하는 안구 혈관신생 질환의 예방 또는 치료용 점안제 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6710030B1 (en) * 1993-10-22 2004-03-23 University Of Southern California Contortrostain (CN) and methods for its use in preventing metastasis and other conditions
US5659018A (en) * 1995-08-01 1997-08-19 Genetics Institute, Inc. Mocarhagin, a cobra venom protease, and therapeutic uses thereof
WO2003042354A2 (en) * 2001-09-04 2003-05-22 Aventis Pharmaceuticals Inc. Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
JP2005529166A (ja) 2002-06-07 2005-09-29 ウィスコンシン アルムニ リサーチ ファウンデーション ペプチドカップリングのための試薬の化学合成
CA2606989A1 (en) * 2005-04-29 2006-11-09 Research Development Foundation Vascular targeting of ocular neovascularization
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
EP2456454A4 (en) * 2009-07-20 2013-03-20 Univ Nat Cheng Kung FOR AV-3-INTEGRIN SELECTIVE POLYPEPTIDE AND PHARMACEUTICAL USES THEREOF ASSOCIATED WITH A HUMAN SERUM ALUMINUM (HSA) VARIATION

Similar Documents

Publication Publication Date Title
RU2012131251A (ru) Композиции и способы для лечения связанных с ангиогенезом заболеваний глаз
US12208091B2 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
JP2015526467A5 (enExample)
KR20200140830A (ko) 에피네프린 스프레이 제제
JP2012525415A5 (enExample)
JP2022512478A5 (enExample)
JP2016506391A5 (enExample)
HRP20170531T1 (hr) Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze
JP2015528454A5 (enExample)
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
JP2020090547A (ja) 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物
JP2017531044A5 (enExample)
CN106413708A (zh) Nmda受体拮抗剂的医药用途及其药物组合物
US9827220B2 (en) Treatment for ischemic stroke
CA3022152C (en) DIPEPTIDYL PEPTIDASE-4 INHIBITORS FOR THE TOPICAL OCULAR TREATMENT OF RETINAL NEURODEGENERATIVE DISEASES
JP2009506978A5 (enExample)
JP2016515137A5 (enExample)
JP2016505050A5 (enExample)
FI3590960T3 (fi) Perifeeristen hermojen IgG-stimuloitu remyelinaatio
JP2009519962A5 (enExample)
JP2019507786A5 (enExample)
RU2014126070A (ru) Способы лечения и предотвращения глазных заболеваний
US20240366729A1 (en) Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea
EP3996717A1 (en) Combination
CN110325214A (zh) 用于预防和治疗神经元损伤的低剂量药物组合